Gliflozins are a novel class of oral anti-diabetic drugs, acting as inhibitors of sodium-glucose
co-transporters (SGLTs) through the proximal convoluted tubules (PCT) and intestinal …

Patients with diabetes are at higher risk of cardiovascular diseases and cognitive
impairment. SGLT2 inhibitors (Empagliflozin, Canagliflozin, Dapagliflozin, Ertugliflozin …

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are oral anti-hyperglycemic agents
approved for the treatment of type 2 diabetes mellitus. Some reports suggest their presence …

The number of diabetic patients has risen dramatically in recent decades, owing mostly to
the rising incidence of type 2 diabetes mellitus (T2DM). Several oral antidiabetic …

ABSTRACT Introduction Sodium Glucose co-Transporter 2 (SGLT2) inhibitors (also known
as 'gliflozins') represent a cornerstone to treat diabetes mellitus. Moreover, recent …

Type 2 diabetes mellitus (T2DM) is a known independent risk factor for atherosclerotic
cardiovascular disease (CVD) and solid epidemiological evidence points to heart failure …

The effects of sodium‐glucose cotransporter 2 (SGLT2) inhibitors on risk of stroke have not
been conclusively established. Therefore, we conducted a meta‐analysis to evaluate the …

Sodium-glucose cotransporter 2 (SGLT2) inhibitors, also known as gliflozins, improve
glycemia by suppressing glucose reuptake in the renal proximal tubule. Currently, SGLT2 …

Sodium-Glucose Cotransporter 2 inhibitors (SGLT2i), or gliflozins, are a group of antidiabetic
drugs that have shown improvement in renal and cardiovascular outcomes in patients with …

Abstract Sodium-glucose transporter 2 (SGLT2) inhibitors, also known as gliflozins, are a
new class of orally active drugs used in the management of type 2 diabetes. By inhibiting the …